Blockchain-based traceability platform VeChain will power the issuance of a limited-edition run of licensed Nike Air Max 1 shoes. Declared on June 24, Australian shoemaker Chase Shiel and retailer The Kickz Stand have associated with creating a limited run of the sneakers — which are also based on Stussy’s ‘SB Dunk’ shoe that was launched in 2005. The shoes will go on sale from June 28 and will be marketed exclusively by Chase Shiel’s website.

VeChain authenticates custom footwear.

The Kickz Stand declared the upcoming limited release of the Air Max 1-inspired shoes on June 24, with a tweet highlighting that the shoes will be traced utilizing VeChain’s ToolChain Suite and Thor Blockchain. The Australian shoemaker first unveiled that they were collaborating with VeChain in November 2019, tweeting that the traceability platform would be leveraged to confirm the authenticity and counterfeit products.

Chase Shiel’s shoes are shipping with VeChain’s tracking chip, which enables consumers and retailers to access detailed product data by scanning a QR code. While the decision to work with a licensed shoe manufacturer to assure the authenticity of non-genuine Nike’s may amuse some, Redditor ‘Nopers5’ believes the blockchain firm is angling to get a call from Nike proper once they spot VeChain’s work with licensees:

“This is the best strategy by Vechain. Target the small shoe companies that have released Nike licensed products, and maybe eventually, Nike comes calling.”

VeChain expands food tracing in China.

At the commencement of this month, VeChain declared collaboration with Walmart subsidiary and premium shopping chain Sam’s Club and the Shenzhen Yuhongtai Foods Company.

The partnership with Sam’s Club will see a revised version of ToolChain employed to trace a variety of food products over their supply chain for Sam’s Club. At the same time, ToolChain will be utilized to track pork products for Yuhongtai’s retailer, Meijiada Fresh Foods. On June 20, VeChain’s medical data management platform ‘I-Dante’ was also launched at the Mediterranean Hospital in the Republic of Cyprus.